DYN - Dyne Therapeutics Inc
IEX Last Trade
46.17
0.910 1.971%
Share volume: 613,341
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$45.26
0.91
2.01%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.95%
1 Month
7.54%
3 Months
47.72%
6 Months
84.51%
1 Year
287.64%
2 Year
356.79%
Key data
Stock price
$46.17
DAY RANGE
N/A - N/A
52 WEEK RANGE
$6.40 - $47.45
52 WEEK CHANGE
$2.92
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/28/2024
Company detail
CEO: Joshua T. Brumm
Region: US
Website: dyne-tx.com
Employees: 135
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: dyne-tx.com
Employees: 135
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.
Recent news